189 related articles for article (PubMed ID: 37016578)
21. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass.
Kinouchi N; Ohsawa Y; Ishimaru N; Ohuchi H; Sunada Y; Hayashi Y; Tanimoto Y; Moriyama K; Noji S
Gene Ther; 2008 Aug; 15(15):1126-30. PubMed ID: 18323791
[TBL] [Abstract][Full Text] [Related]
22. Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice.
Liu CM; Yang Z; Liu CW; Wang R; Tien P; Dale R; Sun LQ
Gene Ther; 2008 Feb; 15(3):155-60. PubMed ID: 18033313
[TBL] [Abstract][Full Text] [Related]
23. Muscle NAD
Hulmi JJ; Penna F; Pöllänen N; Nissinen TA; Hentilä J; Euro L; Lautaoja JH; Ballarò R; Soliymani R; Baumann M; Ritvos O; Pirinen E; Lalowski M
Mol Metab; 2020 Nov; 41():101046. PubMed ID: 32599075
[TBL] [Abstract][Full Text] [Related]
24. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.
Bonetto A; Penna F; Minero VG; Reffo P; Bonelli G; Baccino FM; Costelli P
Curr Cancer Drug Targets; 2009 Aug; 9(5):608-16. PubMed ID: 19508174
[TBL] [Abstract][Full Text] [Related]
25. Assessing Metabolic Dysregulation in Muscle During Cachexia.
Hsu MY; Porporato PE; Wyart E
Methods Mol Biol; 2019; 1928():337-352. PubMed ID: 30725463
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
27. Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.
Siddiqui JA; Pothuraju R; Jain M; Batra SK; Nasser MW
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188359. PubMed ID: 32222610
[TBL] [Abstract][Full Text] [Related]
28. 2-Deoxy-D-glucose Alleviates Cancer Cachexia-Induced Muscle Wasting by Enhancing Ketone Metabolism and Inhibiting the Cori Cycle.
Wei L; Wang R; Wazir J; Lin K; Song S; Li L; Pu W; Zhao C; Wang Y; Su Z; Wang H
Cells; 2022 Sep; 11(19):. PubMed ID: 36230949
[TBL] [Abstract][Full Text] [Related]
29. Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle activation of atrophy.
Castillero E; Akashi H; Wang C; Najjar M; Ji R; Kennel PJ; Sweeney HL; Schulze PC; George I
Biochem Biophys Res Commun; 2015 Jan; 457(1):106-11. PubMed ID: 25528587
[TBL] [Abstract][Full Text] [Related]
30. Effects of the beta
Salazar-Degracia A; Busquets S; Argilés JM; Bargalló-Gispert N; López-Soriano FJ; Barreiro E
Biochimie; 2018 Jun; 149():79-91. PubMed ID: 29654866
[TBL] [Abstract][Full Text] [Related]
31. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
32. Cancer cachexia: mediators, signaling, and metabolic pathways.
Fearon KC; Glass DJ; Guttridge DC
Cell Metab; 2012 Aug; 16(2):153-66. PubMed ID: 22795476
[TBL] [Abstract][Full Text] [Related]
33. DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Ras-ERK pathway.
Masuzawa R; Takahashi K; Takano K; Nishino I; Sakai T; Endo T
J Biochem; 2022 Jan; 171(1):109-122. PubMed ID: 34676394
[TBL] [Abstract][Full Text] [Related]
34. Myokines in treatment-naïve patients with cancer-associated cachexia.
de Castro GS; Correia-Lima J; Simoes E; Orsso CE; Xiao J; Gama LR; Gomes SP; Gonçalves DC; Costa RGF; Radloff K; Lenz U; Taranko AE; Bin FC; Formiga FB; de Godoy LGL; de Souza RP; Nucci LHA; Feitoza M; de Castro CC; Tokeshi F; Alcantara PSM; Otoch JP; Ramos AF; Laviano A; Coletti D; Mazurak VC; Prado CM; Seelaender M
Clin Nutr; 2021 Apr; 40(4):2443-2455. PubMed ID: 33190987
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
36. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
37. Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.
Cerquone Perpetuini A; Re Cecconi AD; Chiappa M; Martinelli GB; Fuoco C; Desiderio G; Castagnoli L; Gargioli C; Piccirillo R; Cesareni G
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):727-746. PubMed ID: 29781585
[TBL] [Abstract][Full Text] [Related]
38. Muscle myostatin signalling is enhanced in experimental cancer cachexia.
Costelli P; Muscaritoli M; Bonetto A; Penna F; Reffo P; Bossola M; Bonelli G; Doglietto GB; Baccino FM; Rossi Fanelli F
Eur J Clin Invest; 2008 Jul; 38(7):531-8. PubMed ID: 18578694
[TBL] [Abstract][Full Text] [Related]
39. Impact of cancer cachexia on respiratory muscle function and the therapeutic potential of exercise.
Murphy BT; Mackrill JJ; O'Halloran KD
J Physiol; 2022 Dec; 600(23):4979-5004. PubMed ID: 36251564
[TBL] [Abstract][Full Text] [Related]
40. A novel orthotopic mouse model replicates human lung cancer cachexia.
van de Worp WRPH; Theys J; González AS; van der Heyden B; Verhaegen F; Hauser D; Caiment F; Smeets HJM; Schols AMWJ; van Helvoort A; Langen RCJ
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1410-1423. PubMed ID: 37025071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
